COLEC11

Across TCGA pan-cancer cohorts, COLEC11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COLEC11 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher COLEC11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COLEC11 expression acts as an unfavorable survival marker.

HNSC, LUSC, and LUAD are the cancer types where COLEC11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.150	0.663	<.001	50	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
LUAD	OS	Median	All	0.274	0.790	.001	9	view →
COAD	OS	Median	All	0.539	0.875	.001	9	view →
SKCM	DFS	Median	III,IV	0.058	0.613	.002	6	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COLEC11–HNSC (OS)

Open the HNSC breakdown →